I recently received a tip on CARN. They are based in Irving, Texas, and specialize in the development of carbohydrare-based therapeutics for the treatment of major illnesses and wounds. They have a new product line (DiaB), which is targeted for diabetics who suffer from lower extermety ulcers.
The stock has been beaten down to all-time lows, (sub-$10), yet insiders are purchasing large blocks of the stock. The stock has traded as high as $50/share.
Does anyone follow this comppany, and if so, what are the prospects for the new product line and other develpomental drugs that they may have in the pipeline?
Good luck, and good investing!
Don Doney |
